leflunomide

Aventis registered, EU (psoriatic arthritis)

Aventis announced on 23 June 2004 that the European Commission has approved leflunomide (ARAVA) for the treatment of adult patients with active psoriatic arthritis. Leflunomide, an inhibitor of tyrosine kinase and dihydroorotate dehydrogenase, is marketed in various countries worldwide, including the USA and Europe, for the treatment of rheumatoid arthritis.

Lead Story from Drug News 23 July 2004

Drug News covers the latest stories on R&D developments worldwide. Drug News is issued weekly and costs £375 for a year's subscription. For a detailed profile and analysis of drugs in R&D see R&D Focus Click here to request further information on Drug News

<< Back to Market Insight